Choose Your Country or Region

Anti-δ Sarcoglycan Rabbit Antibody [K7B23]

Catalog No.: F3978

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000-1:10000 IP1:10 - 1:100 IHC1:100 - 1:250

Application
WB, IP, IHC

Reactivity
Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
32 kDa 35 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Positive Control	Human heart; Human fetal heart; Human skeletal muscle
Negative Control

Datasheet & SDS

Biological Description

Specificity
δ Sarcoglycan Rabbit mAb detects endogenous levels of total δ Sarcoglycan protein.

Clone
K7B23

Synonym(s)
Delta-sarcoglycan, Delta-SG, 35 kDa dystrophin-associated glycoprotein, 35DAG, SGCD

Background
δ-Sarcoglycan is a type II transmembrane glycoprotein and a core component of the sarcoglycan complex within the dystrophin-glycoprotein complex (DGC), which stabilizes the plasma membrane in muscle cells. Structurally, it contains a short cytoplasmic N-terminus, a single transmembrane domain, an extracellular region with one N-linked glycosylation site, and a conserved cysteine-rich cluster at the C-terminus resembling epidermal growth factor–like motifs, although an alternatively spliced form lacking this region is also expressed. δ-Sarcoglycan is highly homologous to γ-sarcoglycan and likely arose via gene duplication, with its gene located on human chromosome 5q31. It is expressed in both striated and smooth muscle, including vascular smooth muscle, where it helps maintain sarcolemmal integrity. Functionally, δ-sarcoglycan contributes to the mechanical stability of muscle fibers, and its disruption leads to destabilization of the sarcoglycan complex and the DGC. Recessive mutations in its gene cause limb-girdle muscular dystrophy type 2F, while some dominant mutations are linked to familial dilated cardiomyopathy, underscoring its critical role in both skeletal and cardiac muscle function.

Background

δ-Sarcoglycan is a type II transmembrane glycoprotein and a core component of the sarcoglycan complex within the dystrophin-glycoprotein complex (DGC), which stabilizes the plasma membrane in muscle cells. Structurally, it contains a short cytoplasmic N-terminus, a single transmembrane domain, an extracellular region with one N-linked glycosylation site, and a conserved cysteine-rich cluster at the C-terminus resembling epidermal growth factor–like motifs, although an alternatively spliced form lacking this region is also expressed. δ-Sarcoglycan is highly homologous to γ-sarcoglycan and likely arose via gene duplication, with its gene located on human chromosome 5q31. It is expressed in both striated and smooth muscle, including vascular smooth muscle, where it helps maintain sarcolemmal integrity. Functionally, δ-sarcoglycan contributes to the mechanical stability of muscle fibers, and its disruption leads to destabilization of the sarcoglycan complex and the DGC. Recessive mutations in its gene cause limb-girdle muscular dystrophy type 2F, while some dominant mutations are linked to familial dilated cardiomyopathy, underscoring its critical role in both skeletal and cardiac muscle function.

References
https://www.ncbi.nlm.nih.gov/books/NBK6317/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%